|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Solid phase microextraction chemical biopsy tool for monitoring of doxorubicin residue during in vivo lung chemo-perfusion显示文摘Development of a novel in vivo lung perfusion(IVLP)procedure allows localized delivery of high-dose doxorubicin(DOX)for targeting residual micrometastatic disease in the lungs.However,DOX delivery via IVLP requires careful monitoring of drug level to ensure tissue concentrations of this agent remain in the therapeutic window.A small dimension nitinol wire coated with a sorbent of biocompatible morphology(Bio-SPME)has been clinically evaluated for in vivo lung tissue extraction and determination of DOX and its key metabolites.The in vivo Bio-SPME-IVLP experiments were performed on pig model over various(150 and 225 mg/m^(2))drug doses,and during human clinical trial.Two patients with metastatic osteosarcoma were treated with a single 5 and 7 μg/mL(respectively)dose of DOX during a 3-h IVLP.In both pig and human cases,DOX tissue levels presented similar trends during IVLP.Human lung tissue concentrations of drug ranged between 15 and 293 μg/g over the course of the IVLP procedure.In addition to DOX levels,Bio-SPME followed by liquid chromatography-mass spectrometry analysis generated 64 metabolic features during endogenous metabolite screening,providing information about lung status during drug administration.Real-time monitoring of DOX levels in the lungs can be performed effectively throughout the IVLP procedure by in vivo Bio-SPME chemical biopsy approach.Bio-SPME also extracted various endogenous molecules,thus providing a real-time snapshot of the physiology of the cells,which might assist in the tailoring of personalized treatment strategy. | Barbara Bojko Nikita Looby Mariola Olkowicz Anna Roszkowska Bogumiła Kupcewicz Pedro Reck dos Santos Khaled Ramadan Shaf Keshavjee Thomas K.Waddell German Goomez-Rios Marcos Tascon Krzysztof Gorynski Marcelo Cypel Janusz Pawliszyn | 2021 | Journal of Pharmaceutical Analysis2021，11，1： | 3 |
| 2 | 金属载体催化转化器在摩托车上的应用显示文摘1德国依米泰克公司介绍
随着世界范围内机动车排放法规的日益严格,对车用催化转化器的要求也越来越高.由于金属材料在物理特性上具有许多优点,金属载体对催化转化率及发动机动力性能、经济性能都具有积极影响,具有广阔的发展前景. | Alfred Reck | 2004 | 摩托车技术2004，，11： | 2 |
| 3 | A new spectrophotometic method for determination of 5-nucleotidase显示文摘 | Heinz F Pilz R Reckes | 1980 | J Clin Chem Biochem1980，18，： | 2 |
| 4 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study显示文摘 | Thomas J. Lynch Igor Bondarenko Alexander Luft Piotr Serwatowski Fabrice Barlesi Raju Chacko Martin Sebastian Joel Neal Haolan Lu Jean-Marie Cuillerot Martin Reck | 2012 | Journal of Clinical Oncology2012，，17： | 2 |
| 5 | Bubble size estimation for flotation processes显示文摘 | Lin B Recke B Knudsen J K H | 2008 | Minerals Engineering2008，21，7： | 1 |
| 6 | Phase III trial of cispl-atin plus gemcitabine with either placebo or bevacizumab asfirst-line therapy for nonsquamous non-small-cell lung cancer:Avail显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 7 | Final safety results of BO17704(A-VAiL):a phase III randomized study of first-line bevacizumab(BV)and cisplatin/gemcitabine(CG)in patients(pts)with ad-vanced or recurrent nonsquamous non-small cell lung cancer(NSCLC)显示文摘 | Hirsh V Ramlau R von Pawel J Zatloukal P Vera G Leighl N Mezger J Archer V Reck M | 2009 | J Clin Oncol2009，，： | 1 |
| 8 | Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab ( BV ) -based first-line therapy 显示文摘 | Archer V Reck M Sandier AB | 2008 | J Clin Oncol2008，26，： | 1 |
| 9 | The energy benefit of stainless steel recycling 显示文摘 | JOHNSON J RECK B K WANG T GRAEDEL T E | 2008 | Energy Policy2008，36，1： | 1 |
| 10 | Management of non-small-cell lung cancer: recent developments显示文摘 | Reck M Heigener DF Mok T | 2013 | Lancet2013，382，9893： | 1 |
| 11 | A buyer's bases of power显示文摘 | Naumann E Reck R | | 0，，04： | 1 |
| 12 | Diagnostic sensitivity and apecificity Of Doppler ultrasound in rheumatoid arthritis 显示文摘 | Tendev L yon der Recke P Torp-Pedersen S | 2008 | J Rheumatol2008，35，1： | 1 |
| 13 | PhaseⅢtrial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer:AVAil显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 14 | Purchasing: a competitive weapon显示文摘 | Long B G | 1988 | Journal of Purchasing and Materials Management1988，24，3： | 1 |
| 15 | Overall survival with cispl- atin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL)显示文摘 | Reck M yon Pawel J Zatloukal P | 2010 | Ann Oncol2010，21，9： | 1 |
| 16 | PhaseⅢ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil显示文摘 | Reck M von Pawel J Zatloukal P | | 0，，： | 1 |
| 17 | Phenotypic heterogeneity may occur in congenital fibrosis of the extraocular muscles显示文摘 | Reck AC Manners R Hatchwell E | 1998 | Br J Ophthalmol1998，82，5： | 1 |
| 18 | Enterprise resource planning systems:comparing firm performance of adopters and nonadopters显示文摘 | Hunton J E Lippincott B Reck J L | 2003 | International Journal of Accounting Information Systems2003，，4： | 1 |
| 19 | Phase El trial of cispl-atin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 20 | Examining the safety profile of angiogenesis inhibitors : im- plications for clinical practice 显示文摘 | Reck M | 2010 | Target Oncol2010，5，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员